Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 392 across all filing types
Latest filing 2026-05-15 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思2025 年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed and detailed vote counts at the 2025 Annual General Meeting (AGM) of the company. It provides the voting results for each agenda item, which fits the definition of "Declaration of Voting Results & Voting Rights Announcements." Therefore, it should be classified as DVA.
2026-05-15 Chinese
安杰思关于注销2025年员工持股计划全部股票并减少注册资本暨通知债权人的公告
Share Issue/Capital Change Classification · 94% confidence The document is an official announcement by Hangzhou Anjiasi Medical Technology Co., Ltd. regarding the cancellation of all shares under its 2025 employee shareholding plan, the concomitant reduction of its registered capital, and notification to creditors under Chinese company law. This is not a financial report but a corporate action affecting share capital levels. Therefore it should be classified as a Share Issue/Capital Change (SHA).
2026-05-15 Chinese
安杰思2025年年度股东会会议资料
AGM Information Classification · 100% confidence The document is titled "2025年年度股东会会议资料" which translates to "2025 Annual General Meeting (AGM) Meeting Materials" for Hangzhou Anjiese Medical Technology Co., Ltd. It contains detailed agenda items for the 2025 AGM, including proposals for approval such as the 2025 Annual Report, Board Work Report, Profit Distribution Plan, Auditor Reappointment, Financial Statements, and other governance and compensation matters. The document includes meeting instructions, agenda, proposals, and supporting reports to be discussed and voted on at the AGM. It is a comprehensive set of materials prepared for the shareholders' meeting rather than the annual report itself or a simple announcement. The length (15,000 characters) and content confirm it is the meeting materials for the AGM. Therefore, the correct classification is AGM Information (AGM-R).
2026-05-06 Chinese
安杰思关于部分募投项目结项并将节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the completion of a fundraising investment project and the permanent allocation of surplus raised funds to working capital. It details the fundraising amount, project completion status, surplus funds, and the company's plan to use these funds. The document includes audit committee opinions, board resolutions, and sponsor opinions, indicating it is a formal disclosure about the use of raised capital. There are no financial statements or comprehensive financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a capital raising announcement itself but an update on the use of previously raised funds. This fits the definition of a Capital/Financing Update (CAP) as it relates to fundraising activities and capital structure changes. The document length is 2630 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2026-04-22 Chinese
安杰思关于修订公司部分管理制度的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the board of directors of Hangzhou Anjiesi Medical Technology Co., Ltd. regarding revisions to certain internal management and governance systems. It references the board meeting date and the need for shareholder approval for some changes. The content focuses on governance and internal control system updates, mentioning compliance with company law and stock exchange listing rules. The document is short (715 characters) and serves as a formal announcement of governance changes, not a full governance report or detailed management report. It does not contain financial data or detailed analysis. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in company board or senior management and related governance matters.
2026-04-22 Chinese
天健审〔2026〕8051号-安杰思2025年年度内控审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It includes an audit opinion on the effectiveness of internal control over financial reporting as of December 31, 2025. The document is issued by a certified public accounting firm and contains detailed audit responsibilities, limitations, and conclusions. The length is 3086 characters, which is relatively short but contains substantive audit content rather than just an announcement. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. It is not an Annual Report (10-K) or Interim Report (IR) because it focuses solely on internal control audit opinion. It is not a Regulatory Filing (RNS) because it contains the actual audit report, not just a certification or announcement. Therefore, the correct classification is AR with high confidence.
2026-04-22 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.